LAWRENCE, Mass., Oct. 25, 2016 /PRNewswire/ -- NxStage Medical,
Inc. (Nasdaq: NXTM), a leading medical technology
company focused on advancing renal care, today announced that six
comprehensive clinical reviews describing the benefits of more
frequent hemodialysis were published in the American Journal of
Kidney Diseases (AJKD).
The research highlights the benefits of more frequent
hemodialysis (typically performed at home) versus conventional
in-center hemodialysis, including:
- Less stress on the heart, particularly through regression of
left ventricular hypertrophy, an important cardiovascular risk
factor;
- Likely lower risks of cardiovascular morbidity and
mortality;
- Lower blood pressure with fewer antihypertensive
medications;
- Lower phosphorus with fewer phosphate binders;
- Improved physical health-related quality of life; and,
- Fewer symptoms of treatment, including intradialytic
hypotension and post-dialysis fatigue.
"The fundamental limitation of conventional hemodialysis is the
difficulty in managing fluid volume and blood pressure. Numerous
studies during the past 15 years, culminating with extensive
evidence gathered from the Frequent Hemodialysis Network trials,
indicate that more frequent hemodialysis can improve volume control
and positively address key cardiovascular risk factors," said Dr.
Allan J. Collins, NxStage senior
medical advisor and professor of medicine at the University of Minnesota. "Just as importantly, more
frequent hemodialysis can improve patient-reported quality of life
and appears to dramatically reduce post-dialysis recovery time, a
major stressor on day-to-day living. Wider application of more
frequent hemodialysis has the potential to improve the health and
well-being of dialysis patients."
"We believe this publication is a powerful resource for the
renal care community," stated Joseph
Turk, president of NxStage. "Physicians can use this wealth
of data to deepen and broaden their understanding of more frequent
hemodialysis to better inform their decisions and help their
patients lead longer and healthier lives."
Currently, over 95% percent of hemodialysis patients in the U.S.
receive treatment three times per week, despite overwhelming
evidence of clinical and lifestyle benefits for patients on more
frequent hemodialysis. The NxStage® System One™ is a simple,
flexible and portable hemodialysis system that provides a wide
range of dialysis therapy options, including home, more frequent
and nocturnal dialysis. Visit www.nxstage.com for more information
on therapy options with the System One.
The clinical reviews can be viewed in their entirety at no cost
by visiting American Journal of Kidney Diseases.
Despite the health benefits that home hemodialysis may
provide to those with chronic kidney disease, this form of therapy
is not for everyone. The reported benefits of home hemodialysis may
not be experienced by all patients. The risks associated with
hemodialysis treatments in any environment include, but are not
limited to, high blood pressure, fluid overload, low blood
pressure, heart-related issues, and vascular access complications.
The medical devices used in hemodialysis therapies may add
additional risks including air entering the bloodstream and blood
loss due to clotting or accidental disconnection of the blood
tubing set. Certain risks are unique to the home. Treatments at
home are done without the presence of medical personnel and on-site
technical support. Patients and their partners must be trained on
what to do and how to get medical or technical help if
needed.
About the NxStage System One
The NxStage System One is
the first and only truly portable hemodialysis system cleared
specifically by the FDA for home hemodialysis and home
nocturnal hemodialysis. Its simplicity and revolutionary size (just
over a foot tall) are intended to allow convenient use in patients'
homes and give patients the freedom to travel with their therapy.
When combined with the NxStage PureFlow SL Dialysis Preparation
System, patients are able to further simplify, using ordinary tap
water to create dialysis fluid on demand. Unlike conventional
hemodialysis systems, the System One requires no special
infrastructure to operate. Under the guidance of their physician,
patients can use the NxStage System One, with their trained
partners, where, how and when it best meets their needs, including
while they are sleeping - at home or on vacation and at a medically
appropriate treatment frequency. In addition, NxStage's Nx2me
Connected Health platform collects important NxStage System One and
patient information for flexible viewing, monitoring and
reporting that may improve patient management and patient
retention, as well as simplify alternative site care.
http://www.nxstage.com/.
About NxStage Medical
NxStage Medical, Inc.
(Nasdaq: NXTM) is a leading medical technology company,
headquartered in Lawrence, Massachusetts, USA, that develops,
manufactures and markets innovative products for the treatment of
end-stage renal disease (ESRD) and acute kidney failure. NxStage
also has established a small number of dialysis clinics committed
to the development of innovative care delivery models for patients
with ESRD. For more information on NxStage and its products and
services, please visit the Company's websites
at www.nxstage.com and www.nxstagekidneycare.com.
Forward-Looking Statements
This release contains
"forward-looking statements" within the meaning of the Private
Securities Litigation Reform Act of 1995. All statements contained
in this release that are not clearly historical in nature are
forward-looking, and the words "anticipate," "believe," "expect,"
"estimate," "plan," and similar expressions are generally intended
to identify forward-looking statements. Actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors including those that are
discussed in NxStage's filings with the Securities and Exchange
Commission, including its Quarterly Report on Form 10-Q for the
quarter ended June 30, 2016. NxStage
is under no obligation to (and expressly disclaims any such
obligation to) update or alter its forward-looking statements,
whether as a result of new information, future events or
otherwise.
Media contact:
Kristen K. Sheppard, Esq.
ksheppard@nxstage.com
Tel: (978) 332-5923
Logo -
http://photos.prnewswire.com/prnh/20110503/MM94799LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nxstage-announces-publication-of-journal-supplement-with-major-clinical-reviews-supporting-more-frequent-hemodialysis-therapy-300350189.html
SOURCE NxStage Medical, Inc.